scholarly journals Anecdote Increases Patient Willingness to Take a Biologic Medication for Psoriasis

2021 ◽  
Vol 108 (2S) ◽  
Author(s):  
Matthew Johnson
Keyword(s):  
Biologic Medication ◽  
Patient Willingness

scholarly journals Patient willingness to take teriparatide

2007 ◽  
Vol 65 (2) ◽  
pp. 237-244 ◽  
Author(s):  
Liana Fraenkel ◽  
Barbara Gulanski ◽  
Dick Wittink
Keyword(s):  
Patient Willingness

scholarly journals An Anchoring-Based Intervention to Increase Patient Willingness to Use Injectable Medication in Psoriasis

2017 ◽  
Vol 153 (9) ◽  
pp. 932 ◽  
Author(s):  
Elias Oussedik ◽  
Leah A. Cardwell ◽  
Nupur U. Patel ◽  
Omobola Onikoyi ◽  
Steven R. Feldman
Keyword(s):  
Willingness To Use ◽  
Patient Willingness

scholarly journals Evaluation of Patient Willingness to Adopt Remote Digital Monitoring for Diabetes Management

2021 ◽  
Vol 4 (1) ◽  
pp. e2033115 ◽  
Author(s):  
Theodora Oikonomidi ◽  
Philippe Ravaud ◽  
Emmanuel Cosson ◽  
Victor Montori ◽  
Viet Thi Tran
Keyword(s):  
Diabetes Management ◽  
Willingness To Adopt ◽  
Digital Monitoring ◽  
Patient Willingness

The Importance of Monitoring the Postpartum Period in Moderate to Severe Crohn’s Disease

2021 ◽  
Author(s):  
Audrey Bennett ◽  
Alexander Mamunes ◽  
Mindy Kim ◽  
Caroline Duley ◽  
Ailish Garrett ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Postpartum Period ◽  
Tertiary Care ◽  
Retrospective Chart Review ◽  
Outpatient Setting ◽  
Smoking During Pregnancy ◽  
Wilcoxon Rank Sum Test ◽  
Increased Risk ◽  
Biologic Medication

Abstract Background Prior research demonstrates Crohn’s disease patients often do well in pregnancy; however, less is known about the risk of flare in the postpartum period. Methods A retrospective chart review was conducted at a tertiary care inflammatory bowel disease center. All pregnant women with Crohn’s disease who were followed in the postpartum period, defined as 6 months after delivery, were included. Statistical analysis included χ 2 analysis, Wilcoxon rank sum test, and logistic regression analysis. The primary outcome of interest was rate of flare in the postpartum period. Results There were 105 patients included in the study, with a majority (68%) on biologic medication during pregnancy. Thirty-one patients (30%) had a postpartum flare at a median of 9 weeks (range 2–24 weeks). Twenty-five patients (81%) had their postpartum flare managed in the outpatient setting with medications (only 4 of these patients required prednisone). 6 of 31 patients (19%) were hospitalized at a median of 4 weeks (range 2–26 weeks) after delivery, requiring intravenous corticosteroids or surgery. In multivariable regression, there was no significant increase in risk of postpartum flare with increasing maternal age, flare during pregnancy, or steroid or biologic use during pregnancy. Smoking during pregnancy increased risk of postpartum flare (odds ratio, 16.2 [1.72–152.94], P < 0.05). Conclusion In a cohort of Crohn’s disease patients, 30% experienced a postpartum flare despite being on medical therapy, but most were able to be managed in the outpatient setting.

scholarly journals Relationship Between Patient Satisfaction and Willingness to Comply With Physicians’ Recommendation in Referral Surgical Outpatient Clinic in Nigeria

2020 ◽  
Vol 7 (6) ◽  
pp. 1556-1562
Author(s):  
KE Okonta ◽  
DS Ogaji
Keyword(s):  
Patient Satisfaction ◽  
Outpatient Clinic ◽  
Short Form ◽  
Drug Prescription ◽  
University Teaching ◽  
Systematic Sampling ◽  
Satisfaction With Care ◽  
Cross Sectional ◽  
The Relationship ◽  
Patient Willingness

The relationship between patient satisfaction with surgical care and their willingness to comply with doctors’ recommendations has not been studied in the country. This study determined the relationship between ambulatory patients’ satisfaction with care and their willingness to adhere to the surgeons’ recommendations in the surgical outpatient clinic (SOPC) of the University Teaching Hospital. This analytical cross-sectional study was conducted among 490 adult respondents at the SOPC selected through a systematic sampling method with a sample interval of 1:2. The short form of the Patient Satisfaction Questionnaire with 7 domains and tool developed for patient willingness to comply with surgeons’ recommendations were used. Descriptive and inferential analyses were performed, and P values of <.05 were considered significant. A total of 466 respondents’ data were analyzed, giving a response rate of 95.1%. About 52.8% were males and 47.2% were females. The associations between domains of patient satisfaction and willingness to surgical instructions were mostly weak and nonsignificant. Their satisfaction with communication with the surgeons was the most consistent predictor of patient willingness and showed significant relationships with their willingness to accept follow-up visits ( P = .002), drug prescription ( P < .001), and further investigation ( P < .001). Access/convenience and general satisfaction were significantly associated with their willingness to recommend the surgery clinic to close friends and relatives. Patient satisfaction with care has a significant relationship with their willingness to adhere to surgical recommendations.

Tu1937 PATIENT WILLINGNESS TO PARTICIPATE IN CELIAC DISEASE CLINICAL TRIALS: GLUTEN CHALLENGE AND NEED FOR BIOPSY ARE BARRIERS TO PARTICIPATION

2020 ◽  
Vol 158 (6) ◽  
pp. S-1225
Author(s):  
Kate T. Avery ◽  
Amy Ratner ◽  
Claire Baker ◽  
Melissa Secord ◽  
Marie Robert ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Celiac Disease ◽  
Willingness To Participate ◽  
Barriers To Participation ◽  
Patient Willingness

scholarly journals De-escalation of IBD Therapy: When, Who, and How?

2019 ◽  
Vol 1 (1) ◽  
Author(s):  
Akbar K Waljee ◽  
Natapat Chaisidhivej ◽  
Sameer D Saini ◽  
Peter D R Higgins
Keyword(s):  
Inflammatory Bowel Disease ◽  
Side Effects ◽  
Biologic Therapy ◽  
Successful Therapy ◽  
Disease Exacerbation ◽  
Inflammatory Bowel ◽  
Practical Guidance ◽  
Biologic Medication ◽  
Risk Of Relapse

Abstract When patients with inflammatory bowel disease reach clinical remission with biologic therapy, a question that often comes up is, “when can I stop my biologic medication?” This is a question fraught with challenges for both physicians and patients. For physicians, there are valid concerns that stepping down from a successful therapy will lead to relapse and disease exacerbation, and that stepping down could lead to anti-biologic antibodies. For patients, the question is often driven by concerns about long-term side effects and costs of biologics. This review provides an overview of the rationale for, and risks of, withdrawal of IBD therapy. Selected studies have shown how to identify subsets of patients in whom de-escalation can be performed with low risk of relapse. Practical guidance on when and how to de-escalate IBD therapy is provided.

Sign in / Sign up

Export Citation Format

Share Document